10:21 AM EDT, 03/17/2026 (MT Newswires) -- Ascendis Pharma ( ASND ) said topline results from a Phase 2 trial of its once-weekly growth hormone, TransCon hGH, showed efficacy and safety comparable to daily somatropin in prepubertal children with Turner syndrome.

The study, which evaluated the hormone also known as lonapegsomatropin, enrolled 49 children, the company said Tuesday in a statement. Children treated with TransCon hGH recorded annualized height velocity at Week 52 similar to children receiving daily somatropin, and the safety and tolerability profile was also comparable, Ascendis said.

Price: 231.25, Change: +0.22, Percent Change: +0.10